A Phase 2 interventional study of Elranatamab in Elranatamab, Myeloma and Multiple Myeloma, sponsored by Pfizer. Completed at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.
Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 24th largest by enrollment, is one of 6 that started in 2021, is one of 18 in phase 2, and was the 7th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Celgene · Sites in United States, Canada, China and 5 more countries
Ages 18+
University of Miami · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 5 · Phase 4 2
First in 2017; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 75 across the 31 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 31 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Multiple Myeloma by Pfizer: 6 open now, 12 under way, 4 of them phase 3. Of 30 finished, 14 (47%) have results posted.
Among the 44 studies in Multiple Myeloma by Pfizer, this one is the 25th largest by enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2021, is one of 7 in phase 2, and was the 24th registered.
Pfizer’s Multiple Myeloma studies by the year they started, since 1999.
7 of the studies testing elranatamab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
| NCT06421675Ontario Clinical Oncology Group (OCOG)Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | 2026-12 |
| NCT06832865Massachusetts General HospitalELISA in Relapsed/Refractory MM | 2026-12-01 |
| NCT06015542Thomas LundSelf-administration of Subcutaneous Elranatamab in the Patients' Homes. | 2026-12-01 |
| NCT06988488CelgeneA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 31 studies testing elranatamab in Multiple Myeloma, from their registry updates:
Among Pfizer’s 44 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma. Multiple myeloma is a form of cancer in the bone that forces healthy blood cells to go out. Sometimes, multiple myeloma does not respond to current therapy or quickly progresses, and this is called refractory multiple myeloma.
Elranatamab is a study medicine that target multiple myeloma and activates the human body to fight against this disease. We are seeking Chinese participants to take part in this study. The study will be 2 parts, called part 1b and part 2. In part 1b, participants will receive Elranatamab at 2 steps priming and full dose as a sc (subcutaneous injection) therapy. We will monitor participants' safety and reactions to the study medicine. This will help us understand the dosage of Elranatamab to be used safely.
In part 2 of the study, participants will receive Elranatamab and their multiple myeloma growth will be monitored. This will help us understand if Elranatamab, when used alone, may be a therapy for refractory multiple myeloma. Participants in this part of the study are expected to take part for about 2 years.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
This study's enrollment of 39 is close to the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms, Plasma Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate BM function characterized by the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BCMA-CD3 bispecific antibody
Drug: Elranatamab
BCMA-CD3 bispecific antibody
Also known as: PF-06863135
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)
Grade(G)4 neutropenia \>5 day; febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/millimeter cube (mm\^3) with single temperature \>38.3 degree Celsius (deg C) or sustained temp\>=38 deg C for \>1 hour(H); G\>=3 neutropenia with infection; G4 thrombocytopenia (unless baseline count \>=25,000/mm\^3 and \<50,000/mm\^3, in which case G4 thrombocytopenia to be accompanied by \>=G2 bleeding); Platelet count \<10,000/mm\^3; G3 thrombocytopenia with \>=G2 bleeding; G\>=4 AE; G3 cytokine release syndrome(CRS) except CRS not maximally treated/improved to \<=G1 within 48H; G3 AE except AE attributed to CRS, G3 nausea,vomiting,diarrhea improved to G\<=2 within 72H after medical management, G3 fatigue \<1 week, G3 AE recovered to baseline/G1 within 5 day; confirmed drug-induced liver injury; G3-4 laboratory (lab) abnormality except G3-4 lab abnormality improved to G\<=2 within 72H after medical management \& without sequelae;G3 injection site reaction; G2/other clinically important AE may be considered DLT.
Time frame: Cycle 1 (28 days)
Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria
ORR: Percentage of participants with best overall response (BOR) of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR and normal serum free light chain (sFLC) ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \& urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein \& reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum \& urine M-protein were unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% \& \>=50% reduction in soft tissue plasmacytomas' size.
Time frame: From date of first dose until confirmed disease progression (PD), death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
Duration of Response (DOR) as Per IMWG Criteria by BICR
DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion, \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
Time frame: From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
DOR as Per IMWG Criteria by Investigator Assessment
DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
Time frame: From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
Complete Response Rate (CRR) as Per IMWG Criteria by BICR
CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/bone marrow aspiration (BMB/BMA) by immunohistochemistry (IH), immunofluorescence (IF), or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.
Time frame: From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
CRR as Per IMWG Criteria by Investigator Assessment
CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.
Time frame: From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
ORR as Per IMWG Criteria by Investigator Assessment
ORR: Percentage of participants with best overall response of confirmed sCR, CR, VGPR or PR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein and urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein were unmeasurable, VGPR and PR: \>=90% and \>=50% decrease in difference respectively between involved and uninvolved sFLC levels and if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.
Time frame: From date of first dose until confirmed PD, death due to any cause, or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Duration of Complete Response (DOCR) as Per IMWG Criteria by BICR
DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
Time frame: From the first documentation of sCR/CR, until confirmed PD, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
DOCR as Per IMWG Criteria by Investigator Assessment
DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
Time frame: From the first documentation of sCR/CR, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
Progression Free Survival (PFS) as Per IMWG Criteria by BICR
PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
Time frame: From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
PFS as Per IMWG Criteria by Investigator Assessment
PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
Time frame: From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
Overall Survival (OS)
OS was defined as time from date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive
Time frame: From the date of first dose until death due to any cause or censoring date (up to 38.8 months of follow-up)
Time-to-Response (TTR) as Per IMWG Criteria by BICR
TTR, for participants with objective response (OR) per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.
Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
TTR as Per IMWG Criteria by Investigator Assessment
TTR, for participants with OR per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.
Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICR
MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.
Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
MRD Negativity Rate Per IMWG Sequencing Criteria by Investigator Assessment
MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.
Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Number of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
AE: any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE): any untoward medical occurrence that, at any dose resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. An AE was considered treatment-emergent if it occurred from the first dose of the study intervention until 90 days after the last dose or the day before starting a new anticancer therapy, whichever occurred first. AEs included both SAEs and all other AEs. AEs were graded using CTCAE version 5.0, where Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening; Grade 5: death. Relatedness to study intervention was judged by investigator.
Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Number of Participants With Cytokine Release Syndrome (CRS) of Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria
ASTCT CRS Grading: Grade 1: temperature \>=38 degree Celsius (deg C) without hypotension or hypoxia; Grade 2: temperature \>=38 deg C with hypotension not requiring vasopressors, and/or hypoxia requiring low-flow nasal cannula, facemask or blow-by; Grade 3: temperature \>=38 deg C with hypotension requiring a vasopressor with or without vasopressin and/or hypoxia requiring high-flow nasal cannula, high-flow facemask, nonrebreather mask, or Venturi mask; Grade 4: temperature \>=38 deg C with hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive pressure (e.g., continuous positive airway pressure \[CPAP\], bilevel positive airway pressure \[BiPAP\], intubation and mechanical ventilation); Grade 5: death. Number of participants with CRS of any grade is reported in this outcome measure.
Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Number of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) of Any Grade According to ASTCT Criteria
ICANS Grade 1: immune effector cell encephalopathy (ICE) score 7-9, participant (P) awakens spontaneously; Grade 2: ICE score 3-6, P awakens to voice; Grade 3: ICE score 0-2, P awakens only to tactile stimulus, any clinical seizure focal or generalized that resolved rapidly/nonconvulsive seizures on electroencephalography that resolved with intervention or focal/local edema on neuroimaging; Grade 4: ICE score 0 (P unarousable and unable to perform ICE), P unarousable/required vigorous/repetitive tactile stimuli to arouse, life-threatening prolonged seizure (\>5 minutes), repetitive clinical/electrical seizures without return to baseline in between, deep focal motor weakness, diffuse cerebral edema on neuroimaging; decerebrate/decorticate posturing; cranial nerve VI palsy; papilledema, Cushing's triad; Grade 5: death. ICE: measures alterations in speech, orientation, handwriting, attention and receptive aphasia. Number of participants with ICANS of any grade reported.
Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Maximum Serum Concentration (Cmax) of Free Elranatamab
Time frame: Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
Time To Maximum Serum Concentration (Tmax) of Free Elranatamab
Time frame: Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free Elranatamab
Time frame: Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
Serum Concentration of Free Elranatamab
Time frame: Predose, 6, 24, and 48 hours post dose on Cycle (C) 1 Day (D) 1; Predose and 24 hours post dose on C1D4; Predose and 6 hours post dose on C1D8; Predose on C1D15; C1D22; C2D1; C3D1; C4D1; C7D1; and C10D1
Percentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against Elranatamab
A participant was ADA or NAb positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-fold dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life of Cancer Participants Core Module (EORTC QLQ-C30) at Cycle 9 Day 1
EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) and a global health status/QoL scale. Functional scales ranged from 0 (low functioning) to 100 (high functioning) where, higher score= higher levels of functioning. Symptom scales ranged from 0 (no symptoms) to 100 (worse symptoms) where, higher scores= worse symptoms/greater burden. Single item scores ranged from 0 (no problem) to 100 (severe problems) where, higher scores= more severe symptoms/problem. The global health status/QoL also ranged from 0 (low health status/QoL) to 100 (good health status/QoL). Higher scores on the global health status/QoL represent higher health status/quality of life.
Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma-Specific Module (EORTC QLQ-MY20) at Cycle 9 Day 1
EORTC QLQ-MY20 is a myeloma-specific module developed by the EORTC group specifically to assess quality of life in participants with multiple myeloma. It contains 20 items which can be grouped into a disease symptom subscale (6 items), side effects of treatment subscale (10 items), body image (1 item) and future perspective subscale (3 items). The Disease Symptoms and Side Effects of Treatment subscale ranged from 0 (no symptoms/side effects) to 100 (worse symptoms/side effects) with higher scores indicating worse symptoms. The Future Perspective and Body Image subscale ranged from 0 (worst support/functioning) to 100 (best support/functioning) with higher scores indicating better support/functioning (Future Perspective and Body Image).
Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ CIPN20) at Cycle 9 Day 1
EORTC QLQ CIPN20 is a module developed by the EORTC group to assess chemotherapy-induced peripheral neuropathy. It contains 20 items which can be grouped into a sensory subscale (9 items), motor subscale (8 items) and autonomic subscale (3 items). Sensory scale scores range from 0 (no sensory symptoms) to 100 (severe sensory symptoms), motor scale scores range from 0 (no motor impairment) to 100 (greater motor impairment), and autonomic scale scores range from 0 (minimal symptoms) to 100 (worse autonomic symptoms). Higher scores indicate worse neuropathy.
Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Change From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Index Score and in EQ-5D Visual Analogue Score (EQ-VAS) at Cycle 9 Day 1
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and VAS. EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, UK look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS. higher scores indicated better health states.
Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Participants with relapsed/refractory multiple myeloma (RRMM), who were refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-cluster of differentiation38 monoclonal antibody (anti-CD38 mAB) were included.
| Milestone | Phase 2 | Phase 1b |
|---|---|---|
| Started | 31 | 8 |
| Treated | 30 | 8 |
| Completed | 0 | 0 |
| Not completed | 31 | 8 |
| Withdrew: Death | 15 | 6 |
| Withdrew: Withdrawal by subject | 8 | 1 |
| Withdrew: Other | 7 | 1 |
| Withdrew: Enrolled but not treated | 1 | 0 |
Grade(G)4 neutropenia \>5 day; febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/millimeter cube (mm\^3) with single temperature \>38.3 degree Celsius (deg C) or sustained temp\>=38 deg C for \>1 hour(H); G\>=3 neutropenia with infection; G4 thrombocytopenia (unless baseline count \>=25,000/mm\^3 and \<50,000/mm\^3, in which case G4 thrombocytopenia to be accompanied by \>=G2 bleeding); Platelet count \<10,000/mm\^3; G3 thrombocytopenia with \>=G2 bleeding; G\>=4 AE; G3 cytokine release syndrome(CRS) except CRS not maximally treated/improved to \<=G1 within 48H; G3 AE except AE attributed to CRS, G3 nausea,vomiting,diarrhea improved to G\<=2 within 72H after medical management, G3 fatigue \<1 week, G3 AE recovered to baseline/G1 within 5 day; confirmed drug-induced liver injury; G3-4 laboratory (lab) abnormality except G3-4 lab abnormality improved to G\<=2 within 72H after medical management \& without sequelae;G3 injection site reaction; G2/other clinically important AE may be considered DLT.
| Participants | Phase 1b |
|---|---|
| Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) | 1 |
ORR: Percentage of participants with best overall response (BOR) of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR and normal serum free light chain (sFLC) ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \& urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein \& reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum \& urine M-protein were unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% \& \>=50% reduction in soft tissue plasmacytomas' size.
| Percentage of participants | Phase 1b | Phase 2 | Phase 1b + Phase 2 |
|---|---|---|---|
| Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria | 37.5 (8.5 to 75.5) | 53.3 (34.3 to 71.7) | 50.0 (33.4 to 66.6) |
DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion, \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
| Months | Phase 1b | Phase 2 | Phase 1b + Phase 2 |
|---|---|---|---|
| Duration of Response (DOR) as Per IMWG Criteria by BICR | 8.7 (7.4 to NA) | 13.7 (2.8 to NA) | 8.7 (3.7 to NA) |
DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
| Months | Phase 1b | Phase 2 | Phase 1b + Phase 2 |
|---|---|---|---|
| DOR as Per IMWG Criteria by Investigator Assessment | 8.7 (7.5 to NA) | NA (3.7 to NA) | 18.5 (6.9 to NA) |
CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/bone marrow aspiration (BMB/BMA) by immunohistochemistry (IH), immunofluorescence (IF), or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.
| Percentage of participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Complete Response Rate (CRR) as Per IMWG Criteria by BICR | 25.0 (3.2 to 65.1) | 21.1 (9.6 to 37.3) | 20.0 (7.7 to 38.6) |
CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.
| Percentage of participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| CRR as Per IMWG Criteria by Investigator Assessment | 25.0 (3.2 to 65.1) | 18.4 (7.7 to 34.3) | 16.7 (5.6 to 34.7) |
ORR: Percentage of participants with best overall response of confirmed sCR, CR, VGPR or PR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein and urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein were unmeasurable, VGPR and PR: \>=90% and \>=50% decrease in difference respectively between involved and uninvolved sFLC levels and if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.
| Percentage of participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| ORR as Per IMWG Criteria by Investigator Assessment | 37.5 (8.5 to 75.5) | 44.7 (28.6 to 61.7) | 46.7 (28.3 to 65.7) |
DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
| Months | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Duration of Complete Response (DOCR) as Per IMWG Criteria by BICR | NA (NA to NA) | NA (1.6 to NA) | NA (1.6 to NA) |
DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
| Months | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| DOCR as Per IMWG Criteria by Investigator Assessment | NA (NA to NA) | NA (1.7 to NA) | NA (1.7 to NA) |
PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
| Months | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Progression Free Survival (PFS) as Per IMWG Criteria by BICR | 1.8 (0.6 to 9.9) | 5.7 (2.2 to 8.0) | 5.7 (2.3 to 8.0) |
PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.
| Months | Phase 1b | Phase 2 | Phase 1b + Phase 2 |
|---|---|---|---|
| PFS as Per IMWG Criteria by Investigator Assessment | 1.8 (0.6 to 9.9) | 5.7 (2.3 to NA) | 5.7 (2.2 to 9.9) |
OS was defined as time from date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive
| Months | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Overall Survival (OS) | 4.0 (1.2 to 14.4) | 9.0 (4.0 to 14.9) | 9.0 (5.5 to 16.7) |
TTR, for participants with objective response (OR) per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.
| Months | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Time-to-Response (TTR) as Per IMWG Criteria by BICR | 2.04 (1.15 to 4.73) | 1.51 (0.95 to 5.52) | 1.45 (0.95 to 5.52) |
TTR, for participants with OR per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.
| Months | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| TTR as Per IMWG Criteria by Investigator Assessment | 2.04 (1.15 to 2.79) | 1.22 (0.95 to 4.01) | 1.2 (0.95 to 4.01) |
MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.
| Percentage of participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICR | 100.0 (15.81 to 100.0) | 85.7 (42.13 to 99.64) | 80.0 (28.36 to 99.49) |
MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.
| Percentage of participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| MRD Negativity Rate Per IMWG Sequencing Criteria by Investigator Assessment | 100.0 (15.81 to 100.0) | 85.7 (42.13 to 99.64) | 80.0 (28.36 to 99.49) |
AE: any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE): any untoward medical occurrence that, at any dose resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. An AE was considered treatment-emergent if it occurred from the first dose of the study intervention until 90 days after the last dose or the day before starting a new anticancer therapy, whichever occurred first. AEs included both SAEs and all other AEs. AEs were graded using CTCAE version 5.0, where Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening; Grade 5: death. Relatedness to study intervention was judged by investigator.
| Participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Participants With TEAEs | 8 | 38 | 30 |
| Participants With Serious TEAEs | 6 | 28 | 22 |
| Participants with Maximum Grade 3 or 4 TEAEs | 4 | 24 | 20 |
| Participants with Maximum Grade 5 TEAEs | 4 | 13 | 9 |
| Participants With Treatment Related TEAEs | 7 | 37 | 30 |
| Participants With Treatment Related Serious TEAEs | 4 | 21 | 17 |
| Participants with Maximum Grade 3 or 4 Treatment Related TEAEs | 5 | 27 | 22 |
| Participants with Maximum Grade 5 Treatment Related TEAEs | 1 | 5 | 4 |
ASTCT CRS Grading: Grade 1: temperature \>=38 degree Celsius (deg C) without hypotension or hypoxia; Grade 2: temperature \>=38 deg C with hypotension not requiring vasopressors, and/or hypoxia requiring low-flow nasal cannula, facemask or blow-by; Grade 3: temperature \>=38 deg C with hypotension requiring a vasopressor with or without vasopressin and/or hypoxia requiring high-flow nasal cannula, high-flow facemask, nonrebreather mask, or Venturi mask; Grade 4: temperature \>=38 deg C with hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive pressure (e.g., continuous positive airway pressure \[CPAP\], bilevel positive airway pressure \[BiPAP\], intubation and mechanical ventilation); Grade 5: death. Number of participants with CRS of any grade is reported in this outcome measure.
| Participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Number of Participants With Cytokine Release Syndrome (CRS) of Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria | 3 | 19 | 16 |
ICANS Grade 1: immune effector cell encephalopathy (ICE) score 7-9, participant (P) awakens spontaneously; Grade 2: ICE score 3-6, P awakens to voice; Grade 3: ICE score 0-2, P awakens only to tactile stimulus, any clinical seizure focal or generalized that resolved rapidly/nonconvulsive seizures on electroencephalography that resolved with intervention or focal/local edema on neuroimaging; Grade 4: ICE score 0 (P unarousable and unable to perform ICE), P unarousable/required vigorous/repetitive tactile stimuli to arouse, life-threatening prolonged seizure (\>5 minutes), repetitive clinical/electrical seizures without return to baseline in between, deep focal motor weakness, diffuse cerebral edema on neuroimaging; decerebrate/decorticate posturing; cranial nerve VI palsy; papilledema, Cushing's triad; Grade 5: death. ICE: measures alterations in speech, orientation, handwriting, attention and receptive aphasia. Number of participants with ICANS of any grade reported.
| Participants | Phase 1b | Phase 1b + Phase 2 | Phase 2 |
|---|---|---|---|
| Number of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) of Any Grade According to ASTCT Criteria | 0 | 0 | 0 |
| Microgram per milliliter | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| Maximum Serum Concentration (Cmax) of Free Elranatamab | 0.8039 ± 24 | 0.8762 ± 66 | 0.842 ± 48 |
| Days | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| Time To Maximum Serum Concentration (Tmax) of Free Elranatamab | 8.0 (6.94 to 11.0) | 7.0 (3.93 to 9.97) | 7.0 (3.93 to 11.0) |
| Microgram*day per milliliter | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free Elranatamab | 3.864 ± 37 | 3.482 ± 74 | 3.653 ± 56 |
| Nanogram per milliliter | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| Predose on C1D1 | NA ± NA | NA ± NA | NA ± NA |
| 6 hours post dose on C1D1 | 80.02 ± 39 | 79.54 ± 81 | 79.85 ± 52 |
| 24 hours post dose on C1D1 | 131.3 ± 41 | 144.1 ± 70 | 133.9 ± 47 |
| 48 hours post dose on C1D1 | 285.3 ± 33 | 230.1 ± 56 | 252.3 ± 47 |
| Predose on C1D4 | 288.2 ± 40 | 272.1 ± 43 | 285.1 ± 40 |
| 24 hours post dose on C1D4 | 445.3 ± 42 | 628.7 ± 94 | 475.4 ± 54 |
| Predose on C1D8 | 757.0 ± 53 | 697.3 ± 72 | 743.7 ± 57 |
| 6 hours post dose on C1D8 | 1148 ± 52 | 1026 ± 81 | 1121 ± 58 |
| Predose on C1D15 | 3097 ± 68 | 2264 ± 104 | 2914 ± 75 |
| Predose on C1D22 | 4511 ± 104 | 3569 ± 128 | 4311 ± 107 |
| Predose on C2D1 | 7960 ± 88 | 7423 ± 48 | 7891 ± 82 |
| Predose on C3D1 | 11470 ± 111 | NA ± NA | 11030 ± 102 |
| Predose on C4D1 | 10980 ± 348 | NA ± NA | 11580 ± 282 |
| Predose on C7D1 | 18410 ± 67 | 68300 | 23930 ± 93 |
| Predose on C10D1 | 13430 ± 29 | 34200 | 15690 ± 49 |
A participant was ADA or NAb positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-fold dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
| Percentage of participants | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| ADA | 4.0 | 0.0 | 3.2 |
| NAb | 4.0 | 0.0 | 3.2 |
EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) and a global health status/QoL scale. Functional scales ranged from 0 (low functioning) to 100 (high functioning) where, higher score= higher levels of functioning. Symptom scales ranged from 0 (no symptoms) to 100 (worse symptoms) where, higher scores= worse symptoms/greater burden. Single item scores ranged from 0 (no problem) to 100 (severe problems) where, higher scores= more severe symptoms/problem. The global health status/QoL also ranged from 0 (low health status/QoL) to 100 (good health status/QoL). Higher scores on the global health status/QoL represent higher health status/quality of life.
| Units on a scale | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| Global QOL | 1.19 ± 13.968 | 5.56 ± 4.811 | 2.5 ± 11.818 |
| Physical Functioning | -11.43 ± 24.859 | 20.0 ± 29.059 | -2.0 ± 28.812 |
| Role Functioning | -14.29 ± 50.395 | 11.11 ± 19.245 | -6.67 ± 43.885 |
| Emotional Functioning | -5.95 ± 14.203 | -2.78 ± 4.811 | -5.0 ± 11.915 |
| Cognitive Functioning | -7.14 ± 21.207 | 0.0 ± 0.0 | -5.0 ± 17.656 |
| Social Functioning | -14.29 ± 33.923 | 5.56 ± 19.245 | -8.33 ± 30.682 |
| Fatigue | 12.7 ± 31.706 | -14.81 ± 12.83 | 4.44 ± 29.722 |
| Nausea and Vomiting | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Pain | 2.38 ± 37.796 | -27.78 ± 25.459 | -6.67 ± 36.175 |
| Dyspnoea | 0.0 ± 0.0 | -11.11 ± 19.245 | -3.33 ± 10.541 |
| Insomnia | 14.29 ± 17.817 | -22.22 ± 19.245 | 3.33 ± 24.595 |
| Appetite Loss | 0.0 ± 19.245 | 22.22 ± 19.245 | 6.67 ± 21.082 |
| Constipation | 14.29 ± 17.817 | 0.0 ± 0.0 | 10.0 ± 16.102 |
| Diarrhea | -4.76 ± 12.599 | -11.11 ± 19.245 | -6.67 ± 14.055 |
| Financial Difficulties | 4.76 ± 23.002 | 0.0 ± 33.333 | 3.33 ± 24.595 |
EORTC QLQ-MY20 is a myeloma-specific module developed by the EORTC group specifically to assess quality of life in participants with multiple myeloma. It contains 20 items which can be grouped into a disease symptom subscale (6 items), side effects of treatment subscale (10 items), body image (1 item) and future perspective subscale (3 items). The Disease Symptoms and Side Effects of Treatment subscale ranged from 0 (no symptoms/side effects) to 100 (worse symptoms/side effects) with higher scores indicating worse symptoms. The Future Perspective and Body Image subscale ranged from 0 (worst support/functioning) to 100 (best support/functioning) with higher scores indicating better support/functioning (Future Perspective and Body Image).
| Units on a scale | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| Body Image | -19.05 ± 37.796 | 11.11 ± 19.245 | -10.0 ± 35.312 |
| Future Perspective | -11.11 ± 15.713 | 0.0 ± 22.222 | -7.78 ± 17.411 |
| Disease Symptoms | -1.59 ± 18.346 | -5.56 ± 11.111 | -2.78 ± 15.984 |
| Side Effects of Treatment | 2.28 ± 9.683 | -7.78 ± 13.461 | -0.74 ± 11.241 |
EORTC QLQ CIPN20 is a module developed by the EORTC group to assess chemotherapy-induced peripheral neuropathy. It contains 20 items which can be grouped into a sensory subscale (9 items), motor subscale (8 items) and autonomic subscale (3 items). Sensory scale scores range from 0 (no sensory symptoms) to 100 (severe sensory symptoms), motor scale scores range from 0 (no motor impairment) to 100 (greater motor impairment), and autonomic scale scores range from 0 (minimal symptoms) to 100 (worse autonomic symptoms). Higher scores indicate worse neuropathy.
| Units on a scale | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| Sensory Subscale | 3.17 ± 10.127 | 0.0 ± 0.0 | 2.22 ± 8.41 |
| Motor Subscale | 10.71 ± 25.057 | -7.54 ± 7.176 | 5.24 ± 22.533 |
| Autonomic Subscale | 3.97 ± 6.964 | -16.67 ± 5.556 | -2.22 ± 11.771 |
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and VAS. EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, UK look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS. higher scores indicated better health states.
| Units on a scale | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| EQ-5D Index Score | -0.06 ± 0.252 | 0.13 ± 0.207 | -0.01 ± 0.246 |
| EQ-VAS | -5 ± 7.07 | 6 ± 5.29 | -1.7 ± 8.23 |
Collected over AEs: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2 | 17/30 (56.7%) | 22/30 (73.3%) | 30/30 (100%) |
| Phase 1b | 6/8 (75%) | 6/8 (75%) | 8/8 (100%) |
| Phase 1b + Phase 2 | 23/38 (60.5%) | 28/38 (73.7%) | 38/38 (100%) |
| Event | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| PneumoniaInfections and infestations | 12/30 | 3/8 | 15/38 |
| AnaemiaBlood and lymphatic system disorders | 0/30 | 1/8 | 1/38 |
| CoagulopathyBlood and lymphatic system disorders | 0/30 | 1/8 | 1/38 |
| NeutropeniaBlood and lymphatic system disorders | 0/30 | 1/8 | 1/38 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/30 | 1/8 | 1/38 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/30 | 1/8 | 1/38 |
| FatigueGeneral disorders | 0/30 | 1/8 | 1/38 |
| Cytokine release syndromeImmune system disorders | 1/30 | 1/8 | 2/38 |
| COVID-19Infections and infestations | 2/30 | 1/8 | 3/38 |
| GastroenteritisInfections and infestations | 0/30 | 1/8 | 1/38 |
| Event | Phase 2 | Phase 1b | Phase 1b + Phase 2 |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 20/30 | 8/8 | 28/38 |
| LeukopeniaBlood and lymphatic system disorders | 21/30 | 7/8 | 28/38 |
| NeutropeniaBlood and lymphatic system disorders | 22/30 | 7/8 | 29/38 |
| AnaemiaBlood and lymphatic system disorders | 20/30 | 6/8 | 26/38 |
| COVID-19Infections and infestations | 20/30 | 3/8 | 23/38 |
| SARS-CoV-2 test positiveInvestigations | 20/30 | 3/8 | 23/38 |
| PneumoniaInfections and infestations | 12/30 | 5/8 | 17/38 |
| HypokalaemiaMetabolism and nutrition disorders | 17/30 | 5/8 | 22/38 |
| HyponatraemiaMetabolism and nutrition disorders | 8/30 | 5/8 | 13/38 |
| LymphopeniaBlood and lymphatic system disorders | 16/30 | 4/8 | 20/38 |
Safety analysis set included all participants enrolled to study who took at least 1 dose of study intervention.
| Age, Continuous(Years) | Phase 1b | Phase 2 | Total |
|---|---|---|---|
| Mean | 54.8 ± 12.19 | 62.3 ± 7.53 | 60.7 ± 9.07 |
| Sex: Female, Male(Participants) | Phase 1b | Phase 2 | Total |
|---|---|---|---|
| Female | 4 | 12 | 16 |
| Male | 4 | 18 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b | Phase 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 30 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1b | Phase 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 30 | 38 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2021 to primary completion in Aug 2023, 19 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 19 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elranatamab